Navigation Links
Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
Date:8/11/2009

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of premium-priced biologics will drive the systemic lupus erythematosus drug market to more than quadruple from approximately $420 million in 2008 to nearly $2 billion in 2018.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the primary drivers of market growth will be the entry and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, Biogen Idec/Roche's ocrelizumab, and Immunomedics/UCB's epratuzumab. In 2018, these three agents, combined with the continued uptake of rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera), will account for more than 80 percent of sales in the systemic lupus erythematosus drug market. In 2008, the market was characterized by extensive use of generics and the majority of sales were driven by the off-label use of two branded agents -- Roche/Galenica's CellCept and rituximab. The off-label use of CellCept, rituximab and other therapies exemplifies the unusual dynamics of the systemic lupus erythematosus market.

"The continued uptake of rituximab, despite its failure in recent clinical trials, highlights the significant challenges associated with drug development for systemic lupus erythematosus, the high unmet need in the indication and the unusual dynamics of this market," said Decision Resources Analyst Dancella Fernandes, Ph.D. "Rituximab's contribution to growth will be greater in the near-term but, from 2013 to 2018, its sales will decline modestly as biosimilar versions of the drug emerge in Europe in 2013 and in the United States in 2015."

The report also finds that the partial replacement of current, predominantly generic, immunosuppressants by branded, premium-priced immunosuppressants will also
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
2. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
3. China Biologic Products Hosts its First Forum for Strategy and Development
4. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
5. MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis.
6. CQ Forum on Biosimilar Biological Products - Wed., June 17, 2009
7. China Biologic Products Closes the $9.6 Million Private Placement
8. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
9. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
10. Results From Neurotechs NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
11. Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ople would like to be able to charge their cell ph...t too often. A recent discovery made by UC San Die...upercapacitors that could do just this. , In re...rs , Prabhakar Bandaru, a professor in the UCSD De...along with graduate student Mark Hoefer, have foun...
(Date:11/19/2009)...BLAUVELT, N.Y., Nov. 19 Dr. Mate H...tract, responds to a press release issued on Novem...an company for making false and self-serving state...es. ,, Dr. Hidvegi stated from his office in B...t research on Avemar does not apply to AveULTRA, ...
(Date:11/19/2009)...BETHESDA, Md., Nov. 19 S... in biotechnology for diabetes therapy, and a prov...es to food, supplement, biotechnology and pharmace...uesday,s Annual Meeting of Shareholders. ,, At ...(Nasdaq: SPEX ) elected the following members to ...
(Date:11/19/2009)...MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeuti...tient in a randomized Phase 2B study of AEG35156, ...lopment for multiple oncology indications. ,, T... 2 Study of the X-Linked Inhibitor of Apoptosis (X...High-dose Cytarabine and Idarubicin in AML Followi...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...lable to Life Science ... SPARK, the region,s,driving force of innovation a... phase of distribution through the Michigan Innova...n,s life science start-ups with valuable,research ...er leading,companies., "MIED is making a signific...
...,GSK) today announced that, beginning in February ...nal and charitable grants provided to US,health-re... a quarterly,basis and will include grants provide...aching institutions, managed care organizations, p... and continuing medical education,companies., GSK...
...irstCall/ --,China-Biotics, Inc. (OTC Bulletin Boa...ing Chinese firm specializing in the manufacture,r...f probiotics products,today announced it signed a ... Co., Ltd. ("Square Pharmaceutical") to supply pro...ed medicines. The agreement runs,through July 2009...
Other Biology Technology:Michigan Innovation Equipment Depot Launches Next Phase of Distribution 2GlaxoSmithKline To Post Quarterly US Grants Report 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3
(Date:11/19/2009)...l with an unwieldy name: 4-hydroxybutyrate (4-HB)....e-rape drug. , Now, a team of Ohio and Michigan...HB is metabolized by the body. "This is new and im...essor and chair of biological sciences at Michigan...arch team. "It may provide new clues on how to co...
(Date:11/19/2009)... 2: The offspring of two inbred strains tend to be... the gene-level variability that leads to this phe... boost our ability to custom-tailor crops for spec...n consumption or high glucose content for biomass ...equence of the common corn strain B73, University ...
(Date:11/19/2009)...inable farming, initially adopted to preserve soil...ole in maintaining a healthy climate, according to...ge and Los Alamos national laboratories. , ORNL ...ial of the earth,s soils to sequester carbon, with...uld greatly reduce U.S. carbon emissions by as muc...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Daily sex helps to reduce sperm DNA damage and improve fertility 50401 1Daily sex helps to reduce sperm DNA damage and improve fertility 50401 2Daily sex helps to reduce sperm DNA damage and improve fertility 50401 3The European Association for the Study of the Liver renews publishing partnership with Elsevier 50397 1New test can detect both genetic and chromosomal abnormalities in embryos 9063 1New test can detect both genetic and chromosomal abnormalities in embryos 9063 2New test can detect both genetic and chromosomal abnormalities in embryos 9063 3
...esearch from the University of Bristol shows that ...ches on in wound cells, wounds can heal faster and...just for wound victims but also for people who suf...al surgery. , When skin is damaged a blood clot f...r the damage, leading to scarring. Scarring is a n...
...NGHAM, Ala. Scientists have pinpointed a set of c... risk for lupus in women who carry them. Some of t...pus patients, which may help future studies examin...racial and ethnic groups, according to a new study...ets important to the search for cutting-edge lupus...
...STER, Minn. -- Featured articles from the January ...ts of antioxidant supplements on cancer, guideline...effectiveness of nasal spray flu vaccine. , May...pplements on Cancer , Do antioxidant supplement...cancer? Thats a question answered by Mayo research...
Other Biology News:Skin care: new research into scar-free healing 2DNA variations signal lupus risk 2DNA variations signal lupus risk 3Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
...plications for the use of small interfering RNA (s... RNA interference (RNAi) pathway have generated tr...ology fields. siRNA for experimental use can be sy...ally, and then transfected into the target cells i...
...ogical data hidden in your samples with eArray and...acturing allows you to create your own microarray ...Design at your own pace and receive delivery of yo...is a secure, online array creation application too...
...les are used to study co-translational and initial...sing events such as signal peptide cleavage, membr...n can be examined by the translation of the approp...somal membranes. In addition, processing and glyco...
Mouse Anti-Human Procollagen type I C-terminal propeptide (PICP) Monoclonal Antibody, Unconjugated from AntibodyShop A/S
Biology Products: